Floatz logo

GSK-2256294A

Pulmonary Disease, Chronic Obstructive

GlaxoSmithKlineSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Pulmonary Disease, Chronic Obstructive cohort.

Asset / SponsorPhaseRating
Liraglutide
Claus Bogh Juhl
Phase 4BB
Roflumilast
Prince of Songkla University
Phase 3BB
Ciprofloxacin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
.ALPHA.-1 PROTEASE INHIBITOR
Takeda
Phase 4BB
Piperacillin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB

View all 50 →

Same molecule, other indications

GSK-2256294A is also rated in:

diabetes mellitusDormant
B
Indicative ·
57 / 100
View asset →
endocrine system disorderDormant
B
Indicative ·
57 / 100
View asset →
glucose metabolism diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →